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Biology of pigmentation 
The primary pigment that determines human skin, 
hair and eye colour is melanin, which is synthesised 
by melanocytes. Melanin protects the skin from 
ultraviolet (UV) radiation and there is an inverse 
correlation between the degree of constitutive pigmentation and the 
risk of sun-induced skin cancers. Besides the life-threatening cancer 
risk, loss of pigmentation results in premature aging, compromised 
cutaneous immunity and significant emotional distress to affected 
individuals.[1-3]
During embryonic development, melanocyte precursors that 
arise from the neural crest populate several areas including the 
interfollicular epidermis and hair follicle bulge in the skin; the uveal 
tract of the eye; and the stria vascularis, vestibular apparatus and 
endolymphatic sac of the ear. The development of melanocytes is 
tightly regulated at the genetic level by a number of genes that control 
proliferation, survival and migration of precursor cells to the various 
sites of the body and their differentiation into active melanocytes. 
A key regulator of this process is the microphthalmia transcription 
factor (MITF), which has been dubbed the ‘master regulator’ of the 
melanocyte, capable of modulating expression of several melanocyte-
specific proteins.[4] MITF mutations result in Waardenburg syndrome 
type II.[5] Once the melanocyte has differentiated, MITF regulates 
expression of genes in response to UV exposure, facilitating the 
tanning response. 
Melanocytes produce two forms of melanin, black-brown 
eumelanin and red-yellow pheomelanin. Skin and hair colour 
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Prashiela Manga joined the Department of Human Genetics at 
the University of Witwatersrand in 1991 as an Honours student 
and went on to complete a PhD in 1997. Both her projects focused 
on mapping genes involved in albinism. Her fascination with the 
biology of pigmentation was fostered by her mentors and co-authors 
on this review, MR and JK, and in no small part by interactions and 
discussions with Trefor Jenkins. PM’s laboratory at the New York 
University School of Medicine continues to focus on unravelling 
the mechanisms involved in regulation of skin pigmentation and 
elucidating the pathobiology of various pigmentation disorders. 
Jennifer Kromberg worked with Trefor Jenkins in his Department 
of Human Genetics from 1971 to 1999 and again later in the same 
department, as a retiree, from 2005 to date. As a social scientist 
she undertook both MA and PhD studies on the psychosocial and 
genetic aspects of oculocutaneous albinism, and has published 
many papers on the topic. During the early 1990s the albinism 
work required a molecular approach and this work was primarily 
guided by Michele Ramsay who had recently returned following a 
postdoctoral fellowship in London. Four molecular PhD projects 
on albinism were completed by students in the department: Mary-
Anne Kedda (nee Colman), Gwyneth Stevens, Prashiela Manga and 
Robyn Kerr. All four have proceeded with careers in science and 
Robyn Kerr is currently an academic member of the Division. It is 
a great pleasure to write this review for the Festschrift in honour of 
Trefor Jenkins’ remarkable academic career.
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is determined by the total amount and ratio of eumelanin to 
pheomelanin. Melanogenesis occurs within membrane-bound 
organelles known as melanosomes. This limits the potential for 
cellular damage by the intermediates of melanin synthesis, which 
include reactive oxygen species. Melanosomes consist primarily of 
proteins that are synthesised in the endoplasmic reticulum (ER) and 
are then routed to the melanosome either directly or via the Golgi 
where additional modifications, such as glycosylation, are made to 
the protein. 
Mutations in a host of genes have been described that result in 
the failure of protein delivery to the melanosome. The majority of 
these comprise the various forms of Hermansky-Pudlak syndrome. 
To date, at least nine forms have been described, each due to 
mutations in a different gene. In addition to oculocutaneous albinism 
(OCA), affected individuals lack platelet-dense bodies, causing a 
bleeding diathesis, and can experience granulomatous colitis or fatal 
pulmonary fibrosis.[6]
Once the key enzymes, including tyrosinase, and structural 
proteins have been delivered, melanin synthesis begins. Melanin 
fills the melanosome, which is transported to the dendrites of the 
melanocyte and is eventually transferred to the keratinocytes where 
it forms a nuclear cap that protects DNA from UV-induced damage. 
In white skin, melanosomes are small, not very heavily pigmented 
and form membrane-bound clusters in the keratinocytes that are 
eventually degraded generating ‘melanin dust’ in suprabasal layers 
of the skin.[7] In black skin, melanosomes are large and remain as 
single organelles throughout the skin, while both forms are found 
in Asian skin.[8] 
Over a hundred genes are thought to play a role in melanin 
synthesis and melanocyte function; however, only 11 have been 
confirmed as key determinants of normal skin pigment variation 
through genome-wide association studies to date,[9] with some genes 
linked exclusively to either inter- or intra-population variation. Fewer 
genes have been implicated in determining hair and eye colour, with 
the melanocortin-1 receptor (MC1R) shown to be the ‘red hair’ 
gene[10] and OCA2 the ‘brown eyes’ gene.[11]
OCA
OCA denotes a group of common autosomal recessive disorders 
resulting from disruption of melanin synthesis. There are four major 
forms: (i) OCA1 (mutated tyrosinase (TYR) gene);[12] (ii) OCA2 
(mutated OCA2 gene);[13] (iii) OCA3 (mutated tyrosinase-related 
protein 1 (TYRP1) gene);[14] and (iv) OCA4 (mutated solute carrier 
family 45, member 2 (SLC45A2) gene).[15] OCAs are characterised 
by decreased or absent melanin in skin, hair and eyes. Lacking 
photoprotection provided by melanin, individuals with OCA are 
highly susceptible to skin cancers, particularly squamous cell 
carcinoma. 
A loss of visual acuity is also a consequence of OCA. During 
development, decreased melanin synthesis in the retinal pigment 
epithelium results in foveal hypoplasia and dysregulation of adjacent 
retinal ganglion cells, and consequently, misrouted decussation of the 
nerve fibres connecting the retina to the brain at the optic chiasm. 
Melanin also plays a role in the adult eyes where it is important 
for reducing light scatter and improving acuity. Individuals with 
OCA thus experience nystagmus, strabismus and photophobia. A 
significant number of children in southern African schools for the 
blind suffer from OCA.
In addition to the physiological issues, the highly visible nature 
of the OCA phenotype, particularly in black communities, causes 
significant psychosocial co-morbidities. These include maternal 
rejection in infancy,[16] later adjustment problems and stigmatisation 
due in part to the widely believed death myth that people with 
albinism do not die normal deaths, but disappear at the end of their 
lives.[17] A study of Nigerians with OCA2 found that they experienced 
alienation, avoided social interactions and were less emotionally 
stable. Furthermore, affected individuals were less likely to complete 
schooling, find employment and find partners.[18]
Albinism occurs at high frequencies in populations of African 
origin. OCA2 is particularly common, with a few mutations 
accounting for most cases, suggesting a shared genetic history.[20] 
Several factors may have contributed to the retention of albinism-
causing mutations: (i) carriers with lighter skin are considered more 
suitable mates; (ii) fertility advantage; and (iii) carrier advantage such 
as reduced susceptibility to disease (e.g. lighter skin may result in 
fewer mosquito bites and a reduced risk of malaria).
Molecular and biochemical basis
The biochemical basis of albinism was first speculated by Garrod 
in 1908 as an inborn error of metabolism.[19] He correctly theorised 
that the phenotype was due to the absence of enzyme activity. The 
enzyme in question is tyrosinase, the key melanogenic enzyme 
that catalyses the first biosynthesis reaction converting tyrosine to 
L-3,4-dihydroxyphenylalanine (L-DOPA). The maturation process 
required to generate a functional tyrosinase enzyme is complex and 
highly regulated. Maturation begins in the ER where chaperones 
facilitate folding, post-translational modification and acquisition 
of tertiary structure. Further modifications are made in the Golgi 
before tyrosinase is transported to melanosomes. Mutations that 
result in OCA1-4 all result in retention of tyrosinase in the ER and/or 
misrouting that prevents delivery to the melanosome. One approach 
to promote tyrosinase maturation in melanocytes in culture is to 
increase the levels of tyrosine or L-DOPA, which accounts for an 
early observation, prior to genetic classification of albinism, that 
hairbulbs incubated in high levels of tyrosine could indicate whether 
the type of OCA was tyrosinase-negative (no increase in melanin) or 
-positive (heavily pigmented hairbulbs post incubation).
OCA1
OCA1 is an autosomal recessive disorder caused by TYR mutations. 
To date, more than 100 mutations have been described at this locus. 
OCA1 has been reported throughout the world and occurs with a 
frequency of about 1/40 000 worldwide, with the highest prevalence 
in white populations.[12] It is extremely rare in black populations.[21] 
OCA1 presents at birth with a range in severities. The most severe 
phenotype, OCA1A or tyrosinase-negative albinism, results from a 
complete lack of enzyme activity and pigment remains completely 
absent in the skin, hair and eyes throughout life. Hypopigmentation is 
accompanied by a severe ocular phenotype. Milder mutations encode 
proteins with some residual enzyme activity that result in slightly less 
severe phenotypes. These include OCA1B (affected individuals are 
born with white skin and hair but develop some pigment with age 
and express less severe ocular findings than in OCA1A), OCA1TS 
(tyrosinase is temperature-sensitive and active in cooler regions of 
the body resulting in a phenotype similar to that of the Siamese cat) 
and platinum OCA (small amounts of pigment accumulate in the hair 
and eyes in late childhood resulting in a silver tinge).[22] A recent study 
identified a potential therapeutic for OCA1 where some tyrosinase 
activity is present. Onojafe et al.,[23] having noted that nitisinone 
(used in the treatment of hereditary tyrosinemia type 1) caused an 
increase in serum tyrosine levels, treated OCA1B mice with the drug 
and noted an improvement in pigmentation of the mice.[23] This is the 
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first potential therapeutic treatment of OCA and may even be of use 
in prenatal treatment to prevent the optic tract misrouting that results 
in loss of visual acuity. The effects of nitisinone on a developing fetus 
are not known; however, at least one patient has been reported to 
have had a successful pregnancy while taking nitisinone,[24] although 
no clinical studies have been performed to date. 
OCA2
OCA2 is the most common form of albinism worldwide due to 
its high prevalence in southern Africa, where it occurs in 1/3  900 
blacks. [21] Affected individuals are born with some pigmentation and 
there is a slight increase in pigmentation with age. Hair colour ranges 
from yellow to light brown, while the skin is white. In some families, 
affected individuals develop multiple freckles in sun-exposed areas. 
Ocular findings are generally less severe than those in OCA1A.
OCA2 results from mutations in the human homologue of the 
mouse pink-eyed dilution gene, OCA2 (formally known as the 
P gene). The OCA2 gene is predicted to encode a transport or channel 
protein,[25] although its precise function is not known. OCA2 was 
mapped to human chromosome 15q11-12 and showed evidence 
of locus homogeneity in black South African (SA) families with 
OCA2. [26] OCA2-associated haplotypes suggested multiple mutations 
and mutation analysis revealed one common mutation, a 2.7  kb 
deletion of exon 7, among these families.[20]
The origin of the deletion has been traced back to a founding 
mutation in central Africa.[20] In parts of Africa, including SA, 
about 80% of OCA2 chromosomes will carry the deletion, making 
it a useful diagnostic tool. A subsequent study investigating non-
2.7 kb alleles in affected individuals from different regions in Africa 
(including SA, Lesotho, Zimbabwe and the Central African Republic) 
found no second common mutation.[27]
OCA2B, known as brown albinism (Fig. 1), is much milder 
than OCA1 and OCA2. It was first described in Nigeria,[28] but we 
have since shown that it is a milder form of OCA2 resulting from 
mutations in the OCA2 gene.[29] Individuals with brown albinism 
have a cream to tan skin, beige to light brown hair and blue-green to 
brown irides. Freckles, similar to those seen in OCA2, may develop 
in sun-exposed areas. 
OCA3
OCA3 (also known as rufous OCA) results from autosomal recessive 
mutations at the TYRP1 locus, at least in patients of African 
descent. Like OCA2, the precise function of this gene is not known, 
however, pigment production is significantly reduced in its absence. 
The prevalence of OCA3 among southern African blacks is at 
least 1/8  580, with a carrier rate of approximately 1/46,[30] while it 
is extremely rare in the remainder of the world. Witkop  et al.[31] 
first described the characteristics of rufous albinism as ‘mahogany 
red to deep red’ hair, reddish-brown skin, occasional presence of 
pigmented nevi or freckles, reddish-brown to brown eye colour, slight 
transillumination of the iris, fundal pigment, nystagmus, photophobia 
and approximately 20/100 visual acuity (Fig.  2). Susceptibility to 
solar damage and skin neoplasia is lower than for OCA2 and brown 
OCA individuals. Affected individuals showed no evidence of 
photoaging, photodamage or carcinomas.[30] Our research identified 
two mutations that result in premature stop codons[29] and account 
for 90% of the mutated TYRP1 alleles in southern African individuals 
with OCA3. Both are nonsense mutations and there is unlikely to be 
any residual enzyme activity. Unlike normal black skin where the 
melanocytes contain mostly mature eumelanosomes, melanocytes in 
OCA3 skin contain both eumelanosomes and phaeomelanosomes at 
various stages of melanisation. Many of the organelles are, however, 
aberrant, ‘crescent’- or racquet-shaped and have melanin only at the 
edges.[32] 
Studies in mouse models have shown that TYRP1, also contributes 
to tyrosinase maturation. In melanocytes lacking TYRP1, tyrosinase 
accumulates in the ER,[33] though to a lesser degree than in OCA2-null 
melanocytes. TYRP1 has also been shown to stabilise tyrosinase,[34] 
leading to the suggestion that TYRP1 is required for transfer of 
tyrosinase from the ER to the Golgi.[35]
Genetic testing for OCA
Identification of the genes involved in these pigmentation disorders 
has facilitated the development of prenatal testing. Several groups 
have demonstrated the utility of genetic testing for albinism and 
five prenatal diagnoses have been carried out in the Human 
Genetics laboratory at the National Health Laboratory Service and 
University of the Witwatersrand, Johannesburg (F Essop, personal 
communication). Given that one mutation accounts for the majority 
of albinism in southern Africa, prenatal diagnosis may be a feasible 
option until effective therapies become available. 
Vitiligo
Another type of pigmentation disorder common in southern Africa 
is vitiligo. Vitiligo affects 1 - 2% of people worldwide, occurring 
Fig. 1. Woman with brown oculocutaneous albinism. 
Fig. 2. Hands of an individual with rufous oculocutaneous albinism.
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with similar frequencies in all ethnic groups. Phenotypically, it is 
characterised by acquired depigmented patches of skin resulting from 
the death of melanocytes. Various forms, defined by the distribution 
of the depigmented lesions, have been identified. These include 
generalised vitiligo (vitiligo vulgaris), the most common form with 
widely distributed, symmetric and progressive lesions; and segmental 
vitiligo, which presents with unilateral depigmented patches. The 
focus of this part of the review will be generalised vitiligo (referred to 
hereinafter as vitiligo). 
Similar to OCA, vitiligo has a major impact on the physical and 
mental health of patients. Melanocyte loss reduces melanin-derived 
photoprotection of the skin and can compromise cutaneous immunity. 
Ocular melanocytes are occasionally lost, causing photophobia 
and night blindness.[36] Depigmentation commonly affects visible 
areas such as the face and hands, which has a significant impact on 
psychological well-being, especially among people of colour. Studies 
have shown that individuals with vitiligo are embarrassed by their 
appearance and usually feel uncomfortable socialising, leading to 
severe depression in some cases and, on rare occasions, suicide.[3] The 
early age of onset, typically in the first two decades of life, exacerbates 
the negative impacts of this disorder, preventing individuals from 
finding employment and even partners.[37]
The pathophysiology of vitiligo is not well understood and there 
are few predictors of disease progression. While some individuals 
experience extensive pigment loss that may eventually affect the 
entire body, others undergo periodic changes in lesion size and 
number. Spontaneous repigmentation due to melanocyte migration 
from perilesional skin or unaffected hair follicles into areas of 
loss has been observed (Fig.  3). Treatments range from the use of 
topical corticosteroids and calcineurin inhibitors to UV combination 
treatments and, in some cases, skin grafting. In addition to potential 
side-effects such as skin atrophy, hyperpigmentation and scarring, 
these therapies are not effective in all patients and may have limited 
long-term results. The lack of new therapies is primarily due to the 
lack of clarity with regard to the aetiology of vitiligo. 
Aetiology
Vitiligo is a multifactorial, non-Mendelian disorder which is associated 
with multiple loci. Vitiligo is thought to occur when melanocytes are 
unable to combat the stress induced by an environmental trigger 
such as severe sunburn, stress, vaccination, radiotherapy or exposure 
to cytotoxins.[38] In individuals genetically susceptible to developing 
vitiligo, the trigger event results in melanocyte dysfunction or death 
that, in turn, initiates an immune response which causes the spread 
of melanocyte loss. While vitiligo does not result in inflammation on 
the scale of skin disorders such as psoriasis, ‘microinflammation’ may 
also contribute to the onset of autoimmunity.[39] 
A genetic component to vitiligo has long been suspected, due to 
the fact that incidence is higher among family members of affected 
individuals than in the general population. Recent genome-wide 
association studies have begun to identify the genetic factors that 
determine susceptibility to vitiligo.[40] 
While the factors that initiate the onset of vitiligo are unclear 
at present, autoimmunity appears to be the mechanism by which 
lesions spread to multiple locations. The presence of antibodies 
targeting melanocyte-specific proteins in sera from patients has 
been reported on multiple occasions. Furthermore, 20 - 25% of 
patients with vitiligo have another autoimmune disorder such 
as psoriasis, diabetes and rheumatoid arthritis.[41] A number of 
immune-related genes have been found to associate with increased 
risk of vitiligo, including major histocompatibility class (MHC) I 
molecules as well as genes involved in autoimmune disorders, such 
as diabetes (UBASH3A and PTPN22) and rheumatoid arthritis 
(C1QTNF6).[40] In addition, melanocyte-specific genes have also 
been associated with increased risk, including OCA2, MC1R and 
TYR, which are thought to be the source of melanocyte-specific 
antigens.[42] 
Oxidative stress and vitiligo 
A constant factor in many hypotheses regarding the pathobiology of 
vitiligo is the involvement of oxidative stress. Studies have suggested 
that individuals with vitiligo have a compromised antioxidant 
response,[43] with enzymes such as catalase and superoxide dismutase 
present at higher than expected levels in tissue from perilesional areas 
and in sera from patients with vitiligo. [44] 
Melanocytes in perilesional sites of vitiligo patients display 
hallmark dilation of the ER.[45] The ER is a sensor of cellular stress. 
Furthermore, protein maturation, which occurs primarily in the ER, 
requires a tightly regulated environment that allows for chemical 
bond formation which determines secondary and tertiary protein 
structure. Thus, disruption of the ER redox balance following cellular 
oxidative stress results in misfolded proteins, which in turn activates 
a stress pathway known as the unfolded protein response (UPR). 
The UPR ameliorates stress caused by accumulation of misfolded 
proteins in the ER by signalling a transient halt in global protein 
synthesis, increasing expression of chaperones that facilitate protein 
folding and increasing degradation of misfolded proteins.[46] The 
Manga laboratory has shown that chemical agents that trigger vitiligo 
induce oxidative stress that activates the UPR, suggesting a role for 
this pathway in the pathogenesis of vitiligo.[47] Interestingly, the UPR 
is activated in other autoimmune disorders such as type I diabetes[48] 
and contributes to activation of the immune response. 
UPR activation in melanocytes results in increased expression of 
cytokines, such as interleukin (IL)-6 and -8 that can attract immune 
components to the skin which initiate an autoimmune response.
[47] These cytokines have been found previously to be expressed at 
higher levels in perilesional compared with normal skin in vitiligo 
patients, suggesting that they may indeed play a role in the aetiology 
of vitiligo. This study thus identified a key link between events that 
trigger vitiligo and the onset of autoimmune disease. 
Conclusion
Decades of work on albinism in SA, influenced by the views and 
contributions of Trefor Jenkins, his students and co-workers, has 
contributed to understanding the social and cultural milieu of 
Fig. 3. Vitiligo lesion displaying repigmentation. (Photo courtesy of SJ Orlow, 
New York University School of Medicine.) 
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albinism, the medical risks and implications, and unravelling the 
molecular basis and aetiology for OCA2 on the sub-continent 
(Table  1). The demystification of albinism and work with the 
Albinism Society of South Africa (http://www.albinism.org.za/), 
under the direction of Nomisonto Masibuko, has contributed to 
acceptance of the condition and empowerment to deal with this 
manageable trait to minimise the adverse effects on the lives of those 
with albinism.
As our understanding of the molecular basis of pigmentation 
improves, effective and long-lasting therapies are likely to become 
a reality for individuals with pigmentary disorders. Demonstrating 
that tyrosinase maturation and trafficking is key to multiple forms 
of OCA may make it feasible to develop a single approach for 
the treatment of multiple forms of OCA, while the identification 
of cytokines involved in the onset of vitiligo may facilitate the 
development of targeted therapies. Chaperones that promote protein 
folding are currently being developed for the treatment of Fabry’s 
disease (Amicus Therapeutics), which results from misfolding of the 
enzyme α-galactosidase A, and antibodies targeting IL-6 are being 
tested for use in the treatment of non-small cell lung cancer.[49] Thus, 
therapies for OCA and vitiligo may now become a reality. 
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